Moreover, we demonstrated that targeting JAK/STAT3 through pretreatment of UC-MSCs with a specific JAK inhibitor AG490, could protect UC-MSCs from senescence and further enhance the therapeutic efficacy in liver fibrosis (Fig. 7). This evidence concerns the gene STAT3 and Hepatic fibrosis.